Editas Medicine, Inc.(EDIT)NASDAQ
Stock Performance & Returns
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
EDIT | 473.0 M | -4.67x | 2.32% | -1.57% | $-0.66 | -1.19% | 0.15 | - | $4.54 | $1.66 |
ZURA | 563.5 M | -5.25x | - | - | $-1.12 | -51.01% | - | - | $7.44 | $1.88 |
XFOR | 400.6 M | 2.83x | 3.46% | - | $1.43 | -1.13% | 0.50 | - | $4.83 | $2.80 |
EBS | 319.4 M | -1.77x | 66.30% | -22.96% | $-3.52 | -40.29% | 1.72 | - | $14.06 | $4.36 |
CYDY | 290.2 M | -7.00x | - | - | $-0.03 | - | - | - | $0.40 | $0.18 |
Peer Valuation & Performance Analysis
Peer group analysis for Editas Medicine, Inc. (EDIT) compared to its primary competitors (including ZURA, XFOR, EBS) reveals distinct metrics. EDIT trades at a valuation discount relative to its competitors, with a P/E ratio of -4.7x versus the peer average of -2.8x (representing a 67% discount). This discount might represent an undervalued entry opportunity or reflect specific risk factors the market is discounting. In terms of growth, EDIT's revenue growth of 2.3% lags behind the peer average of 34.9%, indicating potential market share losses or slower industry adoption. Additionally, it boasts superior profitability with a net margin of -1.6% compared to the peer average of -23.0%, demonstrating strong cost controls and pricing power.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• EDIT ranks #0 in P/E ratio, #3 in revenue growth, and #4 in profit margins
• Average ranking: #2 - 🎯 Top-tier fundamentals relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-09-03 | $3.09 | $3.13 | $3.00 | $3.08 | 1,378,100 | -0.32% |
| 2026-09-02 | $3.09 | $3.23 | $2.98 | $3.08 | 1,678,500 | -0.32% |
| 2026-09-01 | $3.00 | $3.15 | $2.98 | $3.07 | 1,225,200 | +2.33% |
| 2026-08-31 | $3.12 | $3.14 | $3.02 | $3.06 | 2,075,700 | -1.92% |
| 2026-08-28 | $3.25 | $3.41 | $3.15 | $3.16 | 3,270,100 | -2.77% |
| 2026-08-27 | $3.17 | $3.37 | $3.15 | $3.30 | 2,665,000 | +4.10% |
| 2026-08-26 | $3.40 | $3.52 | $3.16 | $3.18 | 2,944,000 | -6.47% |
| 2026-08-25 | $3.05 | $3.33 | $3.05 | $3.28 | 4,210,100 | +7.54% |
| 2026-08-24 | $3.14 | $3.18 | $2.97 | $3.00 | 2,055,800 | -4.46% |
| 2026-08-21 | $2.98 | $3.25 | $2.95 | $3.11 | 2,109,000 | +4.36% |
| 2026-08-20 | $3.17 | $3.23 | $2.92 | $2.94 | 4,262,300 | -7.26% |
| 2026-08-19 | $3.01 | $3.30 | $2.99 | $3.25 | 9,635,400 | +7.97% |
| 2026-08-18 | $2.89 | $2.99 | $2.80 | $2.88 | 2,228,900 | -0.35% |
| 2026-08-17 | $2.80 | $2.90 | $2.77 | $2.84 | 2,113,700 | +1.43% |
| 2026-08-14 | $2.81 | $2.85 | $2.71 | $2.82 | 1,473,100 | +0.36% |
Explore More Analysis for EDIT
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.